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Abstract
We compared the effects of sodium nitroprusside (SNP), and of 8-bromo guanosine 3¢ ,5 ¢ -cyclic monophosphate (8-BrcGMP),
on the 4-aminopyridine (4-AP)-evoked Ca2 + -dependent release of glutamate from hippocampal nerve terminals and further
investigated the role of protein kinase G (PKG) in this mechanism. SNP and 8-BrcGMP dose-dependently inhibited glutamate
release, however SNP concentrations ([SNP]) . 500 mM abolished the 4-AP evoked release, whereas 8-BrcGMP maximally
inhibited the release by about 30%. The inhibition of glutamate release at low concentrations of SNP ( £ 5 mM) was of about 20%,
and was reversed by Rp-8(4-chlorophenylthio)guanosine-3¢ ,5 ¢ -cyclic-monophosphorotioate) (RpCPTcGMP, 50 nM), but the
inhibition at higher concentrations (5 , SNP £ 50 mM) was insensitive to the PKG inhibitor, but sensitive to [1H-(1,2,4)oxadia-
zolo(4,3-a)quinoxalin-1-one] (ODQ), which partially prevented the inhibition. [SNP] . 50 mM strongly inhibited glutamate
release, and this was not reversed by either inhibitor. Furthermore, [SNP] £ 50 mM enhanced cGMP formation, and the observed
effects were not related to either decreased Ca2 + entry or ATP/ADP levels. Our results indicate that NO/PKG is the signaling
pathway underlying the inhibition of glutamate release at low concentrations of NO, and imply that other NO-dependent, but
PKG-independent, mechanisms are activated and have complementary roles at higher NO concentrations. Ó 1999 Elsevier
Science Ireland Ltd. All rights reserved.
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Several studies argue in favor of nitric oxide (NO) acting
as a retrograde messenger to regulate glutamate release in
the brain [5,6,10–12,15]. However, because it potentially
reacts with several intracellular systems, NO has multiple
and often opposing effects at different concentrations of NO
releasing agents. It is, therefore, essential to investigate the
concentration-dependence of the effects of different NO
donors on glutamate release as well as the signaling path-
ways involved. Nevertheless, a sensitive method of contin-
uous measurement of NO concentration to clarify the
physiological significance of the effects of NO is still lack-
ing, whereas nitrate/nitrite formation has been generally
used to determine NO production in higher yield, or longer
time courses [9]. In this study, we used rat hippocampal
synaptosomes, obtained as described elsewhere [4], in an
attempt to elucidate the mechanisms that may be involved in
the effects of NO on the 4-AP evoked Ca2 +-dependent
release of glutamate, as affected by the NO donor SNP or
by a cGMP analog, 8-BrcGMP.
The synaptosomal pellets (1 mg/ aliquot) were main-
tained on ice and used within 4 h. The glutamate release
experiments were preceeded by an incubation period of 45
min, at 30ºC, in a medium containing (in mM): 132 NaCl, 1
KCl, 1 MgCl2, 1.2 H3PO4, 0.1 CaCl2, 10 glucose, 10
HEPES-Na + , supplemented with 0.1 mg/ml BSA. During
the incubation period, SNP, 8-BrcGMP, and/or the appro-
priate inhibitors were added at the 35th min, and were again
included in the glutamate release experiments. The synapto-
somes were collected by centrifugation (15 800 · g for
20 s), and resuspended in 1 ml fresh medium (in mM:
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132 NaCl, 1 KCl, 1 MgCl2, 1.2 H3PO4, 1 CaCl2, 10 glucose,
10 HEPES-Na). The release of glutamate was measured
using a well established [8,11] continuous fluorimetric
assay, based on the GDH-catalyzed reduction of NADP+
in the presence of glutamate. We used a Perkin-Elmer
Model LS-5B fluorimeter (lexc = 340 nm, lem = 460 nm)
coupled to a thermostated (37ºC) chamber with continuous
stirring, and collected data at 2-s intervals. In each experi-
ment, the basal release of glutamate was followed for 5 min,
after which 100 mM 4-AP was added to the suspension, and
the 4-AP evoked release was further monitored for another
5 min, before 2.5 nmol of glutamate were added for calibra-
tion.
At this concentration, the 4-AP evoked glutamate release
is mostly Ca2 +-dependent [11]. Fig. 1A shows that the NO
donor SNP or the cGMP analog, 8-BrcGMP, both dose-
dependently inhibited the Ca2 +-dependent release of gluta-
mate, but to different extents; thus, SNP completely inhib-
ited glutamate release at the higher concentrations tested
( ‡ 500 mM), but 8-BrcGMP maximally inhibited glutamate
release by about 30%. In parallel experiments, SNP signifi-
cantly increased the synaptosomal cGMP levels at low con-
centrations (SNP £ 50 mM), which rapidly decreased to
basal levels at higher concentrations of SNP (Fig. 2).
These results, obtained by radioimmunoassay, were per-
formed on synaptosomes subjected to the same incubation
conditions as in the glutamate release experiments, but
always in the presence of 1 mM zaprinast, a specific
cGMP-dependent phosphodiesterase inhibitor.
Hydroxylamine, another unrelated NO donor, had pre-
viously been shown by our laboratory to have a similar
inhibitory effect on glutamate release and on cGMP levels
in hippocampal synaptosomes [11]. In the previous study,
we had also demonstrated the involvement of cGMP in the
regulation of the 4-AP evoked glutamate release by the
ability of ODQ, a specific guanylyl cyclase inhibitor, to
reverse the inhibition of glutamate release by NO. In the
present study, we show that the concentration of SNP which
stimulated the formation of cGMP inhibited glutamate
release by 20%. These observations strongly correlate
with the inhibition induced by the cGMP analog, 8-BrcGMP
(about 30% of the control) (Fig. 1), as well as by hydroxy-
lamine [11], and imply a role for cGMP at low concentra-
tions of NO. That protein kinase G (PKG) is a potential
effector of cGMP-mediated effects in the brain is now
widely accepted, and it has been demonstrated in a range
of preparations [2,12,13,15]. In the present work, the spe-
cific PKG inhibitor, Rp-8(4-chlorophenylthio)guanosine-
3 ¢ ,5 ¢ -cyclic-monophosphorotioate) (RpCPTcGMP), at 50
nM, reversed the inhibition of glutamate release of
SNP , 5 mM, but not that of higher concentrations,
which do not involve significant cGMP formation (Fig. 3).
Similar results were obtained with hydroxylamine, in which
RpCPTcGMP reversed the inhibitory effect of 30 mM
hydroxylamine on the 4-AP evoked release of glutamate
by about 70% [1]. ODQ, however, completely reversed
the effects of 5 mM SNP, and only partially reversed the
inhibition by 50 mM SNP.
Higher concentrations of RpCPTcGMP did not further
reverse the inhibitory effects of increasing concentrations
of SNP, and, in fact, inhibited the 4-AP evoked release of
Fig. 1. Dose-dependent inhibition of the Ca2+-dependent 4-AP
evoked glutamate release by the NO donor, SNP, or the cGMP
analog, 8-BrcGMP. In each situation, the synaptosomes were
exposed to the drug for 10 min, during incubation, and another 5
min, during the assay, before addition of 4-AP, as detailed in the
text. Data correspond to the % of glutamate release in the control
(3.253 – 0.08 nmol/5 min per mg protein), and each point is the
mean – SEM of 3–5 experiments performed in duplicate. Statistical
significance was evaluated by ANOVA followed by Dunnet’s post
test: **P , 0.01, ***P , 0.001.
Fig. 2. Concentration-response curve for cGMP accumulation in
SNP-treated synaptosomes. As shown, the lower concentrations of
SNP (5 mM) induced the highest cGMP formation. Synaptosomes
were subjected to the same conditions as in the glutamate release
assay (Fig. 1) with the additional presence of 1 mM zaprinast in the
assay medium. Each bar is the mean – SEM of 3–5 experiments
performed in duplicate. Statistical significance was evaluated by
ANOVA followed by Dunnet’s post test: *P , 0.05, **P , 0.01.
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glutamate on it’s own (data not shown), which may reflect
the inhibition of cyclic nucleotide dependent channels
(CNG) as previously suggested [13].
We interpret the results to indicate that cGMP may
directly activate additional signaling effectors at high con-
centrations, which no longer effectively activate PKG, pos-
sibly due to autophosphorylation of PKG as a negative
regulation of that pathway, as suggested in a recent study
by El-Hussein et al. [3], which shows that in the thalamus,
type II PKG is a substrate of NO/cGMP-dependent protein
phosphorylation.
The Ca2 +-dependent release of glutamate occurs upon
membrane depolarization and Ca2 + influx through vol-
tage-dependent calcium channels (VDCC) [8] and there-
fore, one may postulate that NO inhibits glutamate release
by directly, or indirectly through cGMP, blocking calcium
entry. We had previously shown that the inhibition of glu-
tamate release by hydroxylamine does not affect the [Ca2 +]i
in response to 4-AP [11]. To further characterize the Ca2 +
dependence of the inhibitory effects under study, we used
ionomycin, a Ca2 + ionophore, to induce Ca2 + entry into
synaptosomes surpassing the need for VDCC activation,
and the effects of increasing concentrations of SNP or 8-
BrcGMP were tested. As shown in figurehere>Fig. 3B, 50
mM SNP or 25 mM 8-BrcGMP inhibited the ionomycin-
evoked glutamate release, in close resemblance with the
results observed in depolarizing conditions (100 mM 4-
AP) (figurehere>Fig. 3A). In these conditions,
RpCPTcGMP reversed the inhibition of glutamate release
by 8-BrcGMP but not that of SNP (50 mM) which in fact,
slightly increased. These findings exclude the modulation of
VDCC as a target for the cGMP-dependent inhibition of
glutamate release. Similar results were obtained for higher
concentrations of SNP (not shown), and, therefore, it is not
likely altogether that VDCC are negatively modulated by
NO in hippocampal synaptosomes. The question, however,
remains as to which cGMP-independent mechanisms come
into play at the higher concentrations of NO. Several studies
have produced findings with respect to the direct involve-
ment of NO as an effector molecule; S-nitrosylation has
been proposed to affect the interactions among synaptic
vesicle proteins and by bypassing Ca2 + entry, to increase
exocytosis [6,7]. However, in the range of concentrations of
SNP used in the present study, we did not observe enhanced
glutamate release by NO, our data being in agreement with
that of Sistiaga et al. [12], and thus refers to the inhibition of
the Ca2 + -dependent release of glutamate, and not to the
Ca2 +-independent component of release reported by others
to be enhanced by SNP [7]. Yet another study shows that
NO inhibits the glutamate vesicular proton pump by S-nitro-
sylation [14].
In conclusion, the present work shows evidence that in
the hippocampus, PKG is involved in the inhibitory effect of
low concentrations of NO on glutamate release, but does not
account for the inhibition observed at higher concentrations
of NO. However, the data suggest that the overall inhibition
of release, and the signaling mechanisms activated, are
dependent on NO concentration.
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